Understanding genetic factors in Giant Cell Arteritis and Polymyalgia Rheumatica

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to characterize the clinical and immunogenetic aspects of Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR) by recruiting both prospective and retrospective patient cohorts. The primary goal is to identify genetic determinants that contribute to the susceptibility of these conditions, which could provide insights into their underlying mechanisms. Additionally, a subset of patients will be monitored in a post-marketing surveillance registry for those receiving tocilizumab for relapsing or refractory GCA. The study involves multiple centers and focuses on patients aged 50 and above, with a firm diagnosis of GCA or PMR.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Willing to self-identify an ethnic group, such as Caucasian, Asian, Afro-Caribbean.
* Have a firm clinical diagnosis of GCA or PMR, or (for patients identified prospectively) GCA or PMR should be more likely than any alternative explanation for the patient's symptoms.
* Able and willing to give informed consent. Patients will be 50 years of age or over, unless both biopsy-proven and a clinically classical case of GCA.

Exclusion Criteria:

• Patient unwilling or unable to give fully informed consent.

Where it's running

• Queen Elizabeth The Queen Mother Hospital
  Canterbury, Kent, United Kingdom Recruiting
• Whiston Hospital
  Prescot, Merseyside, United Kingdom Recruiting
• Nevill Hall Hospital, Aneurin Bevan University Health Board
  Abergavenny, United Kingdom Recruiting
• Stoke Mandeville Hospital, Buckinghamshire Healthcare NHS Trust
  Aylesbury, United Kingdom Recruiting
• Betsi Cadwaladr University Health Board
  Bangor, United Kingdom Recruiting
• Basildon University Hospital, Basildon and Thurrock University Hospitals NHS Foundation Trust
  Basildon, United Kingdom Recruiting

+26 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Principal investigator: Ann Morgan — University of Leeds
• Study coordinator: Louise Sorensen
• Email: MRCTarget@leeds.ac.uk
• Phone: 0113 343 7764

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding biomarkers in giant cell arteritis and polymyalgia rheumatica

  This study is trying to find specific markers in the blood of people newly diagnosed with giant cell arteritis and polymyalgia rheumatica to help doctors understand their disease better and create personalized treatment plans.

  Recruiting University of Bonn · Bonn, North Rhine-Westphalia · NCT06460142

• National database for Giant Cell Arteritis and Polymyalgia Rheumatica

  This study is trying to see how new imaging techniques can help doctors better manage Giant Cell Arteritis and Polymyalgia Rheumatica by looking at treatment responses and risks in patients.

  Recruiting at 2 sites University of Aarhus · Aarhus and 1 other locations · NCT05935709

• Supplemental hydrocortisone for adrenal insufficiency during stress

  This study is testing if adding hydrocortisone can help people with polymyalgia rheumatica or giant cell arteritis who have low adrenal function feel better during stressful times compared to a placebo.

  Recruiting at 3 sites Phase 4 Copenhagen University Hospital, Rigshospitalet · Aarhus and 2 other locations · NCT05435781

• Registry and biorepository for rheumatic diseases

  This study is collecting samples and health information from adults with rheumatic diseases at Yale clinics to help researchers learn more about these conditions and improve future treatments.

  Recruiting Yale University · New Haven, Connecticut · NCT04402086

• How optic nerve swelling changes after starting steroids in giant cell arteritis

  This study tests how quickly the optic nerve sheath swelling decreases after starting glucocorticoids in people with newly diagnosed giant cell arteritis.

  Recruiting Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal · Montreal, Quebec · NCT07508514

• Sarilumab for early polymyalgia rheumatica in adults

  This study tests whether sarilumab given every two weeks, with a prednisone taper, helps people with early polymyalgia rheumatica more than placebo plus prednisone taper.

  Recruiting at 85 sites Phase 3 Sanofi · Avondale, Arizona and 84 other locations · NCT07286214

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.